You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 42 No. 5, May 1985 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ORIGINAL CONTRIBUTIONS
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (35)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Phenytoin Disposition in Obesity

Determination of Loading Dose

Darrell R. Abernethy, MD, PhD; David J. Greenblatt, MD

Arch Neurol. 1985;42(5):468-471.


Abstract



• Fourteen obese subjects (mean body weight, 124 kg; percent of ideal body weight [IBW], 178%) and ten control subjects of normal body habitus (mean body weight, 67 kg; 92% IBW) received 300 mg of phenytoin sodium by tenminute intravenous infusion. Obese subjects compared with controls had prolonged phenytoin elimination half-life (19.9 v 12.0 hours). Total metabolic clearance of phenytoin was greater in obese than in control groups, although the difference was not significant (59 v 39 mL/ min). Phenytoin half-life, inversely proportional to clearance and directly proportional to volume of distribution (Vd), was prolonged in obesity mainly as a result of the increase in Vd in obese subjects (84 v 40 L). Phenytoin loading dose should be calculated on the basis of IBW plus the product of 1.33 times the excess weight over IBW. Very obese individuals will require large absolute loading doses of phenytoin to rapidly achieve therapeutic drug concentrations.



Author Affiliations



From the Division of Clinical Pharmacology, Departments of Psychiatry and Medicine, Tufts University School of Medicine and New England Medical Center Hospital, Boston. Dr Abernethy is now with Baylor College of Medicine, Houston.


Footnotes



Accepted for publication April 24, 1984.

Reprint requests to Division of Clinical Pharmacology, Box 1007, Tufts—New England Medical Center, 171 Harrison Ave, Boston, MA 02111 (Dr Greenblatt).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dosing dilemmas in obese children
Mulla and Johnson
EDUCATION AND PRACTICE 2010;95:112-117.
ABSTRACT | FULL TEXT  

Pharmacotherapy Overview of Seizure Management in the Adult Emergency Department
Idrees and Londner
Journal of Pharmacy Practice 2005;18:394-411.
ABSTRACT  

The Impact of Obesity and Disease on Busulfan Oral Clearance in Adults
Gibbs et al.
Blood 1999;93:4436-4440.
ABSTRACT | FULL TEXT  

Standards of laboratory practice: antiepileptic drug monitoring
Warner et al.
Clin. Chem. 1998;44:1085-1095.
ABSTRACT | FULL TEXT  

Phenytoin Monitoring in the Intensive Care Unit
Justice
Journal of Pharmacy Practice 1995;8:29-38.
ABSTRACT  

Volume of Distribution of Phenytoin Not Altered in Storage Disease
Goldstein et al.
Arch Neurol 1987;44:577-578.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.